Avadel Pharmaceuticals plc(AVDL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

AVDL Avadel Pharmaceuticals plc

Halted 02-13 16:00:00 EST

21.64

+0.00

0.00%

High21.64	Low21.64	Vol0.00
Open21.64	D1 Closing21.64	Amplitude0.00%
Mkt Cap2.12B	Tradable Cap1.75B	Total Shares98.15M
T/O0.00	T/O Rate0.00%	Tradable Shares80.64M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"AVDL","market":"US","secType":"STK","nameCN":"Avadel Pharmaceuticals plc","latestPrice":21.64,"timestamp":1771016400000,"preClose":21.64,"halted":3,"volume":0,"delay":0,"changeRate":0,"floatShares":80642958,"shares":98153471,"eps":-0.002874,"marketStatus":"Halted","change":0,"latestTime":"02-13 16:00:00 EST","open":21.64,"high":21.64,"low":21.64,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.002874,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1771318800000},"marketStatusCode":7,"adr":1,"adrRate":1,"exchange":"NASDAQ","adjPreClose":21.64,"volumeRatio":0},"requestUrl":"/m/hq/s/AVDL/wiki","defaultTab":"wiki","newsList":[{"id":"2610392713","title":"BRIEF-Alkermes PLC Completes Acquisition Of Avadel Pharmaceuticals PLC, Accelerating Entry Into Sleep Medicine Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2610392713","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610392713?lang=en_us&edition=fundamental","pubTime":"2026-02-12 22:43","pubTimestamp":1770907422,"startTime":"0","endTime":"0","summary":"BRIEF-Alkermes PLC Completes Acquisition Of Avadel Pharmaceuticals PLC, Accelerating Entry Into Sleep Medicine MarketFeb 12 (Reuters) - Alkermes Plc ALKS.O:ALKERMES PLC COMPLETES ACQUISITION OF AVADEL","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nTUA1J0LSJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ALKS","BK4139","AVDL"],"gpt_icon":0},{"id":"2610892941","title":"NASDAQ TRADE HALT  TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 08:10 AM","url":"https://stock-news.laohu8.com/highlight/detail?id=2610892941","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610892941?lang=en_us&edition=fundamental","pubTime":"2026-02-12 21:10","pubTimestamp":1770901843,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 08:10 AM","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nAQN2LLZ14:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AVDL"],"gpt_icon":0},{"id":"2610265829","title":"Avadel Pharmaceuticals Shares Delisted from Nasdaq Following Acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2610265829","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610265829?lang=en_us&edition=fundamental","pubTime":"2026-02-12 20:41","pubTimestamp":1770900061,"startTime":"0","endTime":"0","summary":"Avadel Pharmaceuticals plc will be delisted from the Nasdaq Global Market following its acquisition by Alkermes plc. The delisting process began prior to the opening of trading on February 12, 2026, the same day the acquisition became effective. Avadel also announced that payment of cash consideration to shareholders commenced on February 12, 2026, and shareholders will be recorded as owners of contingent value rights on this date.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avadel Pharmaceuticals plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 12, 2026, and is solely resp","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nNDL1L6k61:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVDL","BK4139","ALKS","BK4007"],"gpt_icon":0},{"id":"2610925121","title":"Alkermes Completes Acquisition of Avadel Pharmaceuticals","url":"https://stock-news.laohu8.com/highlight/detail?id=2610925121","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610925121?lang=en_us&edition=fundamental","pubTime":"2026-02-12 20:30","pubTimestamp":1770899458,"startTime":"0","endTime":"0","summary":"Alkermes plc has completed its acquisition of Avadel Pharmaceuticals plc, adding Avadel’s FDA-approved product, LUMRYZ, to its portfolio and expanding its presence in the sleep medicine market. The deal is supported by approximately $775 million in cash and $1.525 billion in term loans due in 2031. Alkermes expects to pay down the debt quickly with business cash flows and plans to provide 2026 financial expectations for the combined organization in February 2026. The company will record $40 million in transaction-related costs and approximately $180 million in LUMRYZ inventory fair value step-up in 2026. Alkermes highlighted the acquisition as a significant step in its strategy to accelerate growth in sleep medicine and strengthen its commercial capabilities.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only a","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nNDL57NhN6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVDL","ALKS","BK4007","BK4139"],"gpt_icon":0},{"id":"2610925102","title":"Alkermes Plc - Deal Expected to Be Accretive in 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2610925102","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610925102?lang=en_us&edition=fundamental","pubTime":"2026-02-12 20:30","pubTimestamp":1770899400,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nTUA1J0LSJ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ALKS","BK4007","AVDL"],"gpt_icon":0},{"id":"2610640925","title":"Alkermes Plc Completes Acquisition of Avadel Pharmaceuticals Plc, Accelerating Entry Into Sleep Medicine Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2610640925","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610640925?lang=en_us&edition=fundamental","pubTime":"2026-02-12 20:30","pubTimestamp":1770899400,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nTUA1J0LSJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AVDL","ALKS","BK4139","BK4007"],"gpt_icon":0},{"id":"2610160676","title":"Irish Court Approves Avadel Pharmaceuticals Acquisition by Alkermes","url":"https://stock-news.laohu8.com/highlight/detail?id=2610160676","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610160676?lang=en_us&edition=fundamental","pubTime":"2026-02-11 05:07","pubTimestamp":1770757634,"startTime":"0","endTime":"0","summary":"Avadel Pharmaceuticals plc will be acquired by Alkermes plc, following the Irish High Court’s sanction of the arrangement between the two companies. The court approved the acquisition without modification, allowing Alkermes to acquire the entire issued and to be issued ordinary share capital of Avadel. The companies have highlighted that the transaction remains subject to certain conditions and have cautioned that actual outcomes may differ from current expectations due to various risks and uncertainties. This update was disclosed by Avadel Pharmaceuticals.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avadel Pharmaceuticals plc published the original content used to generate this news brief via GlobeNewswire  on February 10, 2026, an","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260210:nNDL9N8SSN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014013.SGD","BK4139","BK4112","NDAQ","SG9999014005.SGD","LU2210149790.SGD","LU0314104364.USD","LU2095319765.USD","SG9999014039.USD","BK4585","BK4588","AVDL","IE00B3QW5Z07.USD","BK4007","IE00BGHQF748.EUR","LU2210150020.SGD","ALKS","IE00BKPKM429.USD","IE00B64PRP62.GBP","SG9999014021.USD"],"gpt_icon":0},{"id":"2604194798","title":"Avadel Pharmaceuticals- Ireland High Court Sets Hearing for Avadel's Scheme on Alkermes for Feb 10, 2026 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2604194798","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604194798?lang=en_us&edition=fundamental","pubTime":"2026-01-20 19:05","pubTimestamp":1768907139,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260120:nFWN3YL015:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AVDL","BK4007"],"gpt_icon":0},{"id":"2604942421","title":"Irish Court Sets Date to Sanction Avadel Pharmaceuticals Acquisition by Alkermes","url":"https://stock-news.laohu8.com/highlight/detail?id=2604942421","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604942421?lang=en_us&edition=fundamental","pubTime":"2026-01-20 19:03","pubTimestamp":1768907023,"startTime":"0","endTime":"0","summary":"Avadel Pharmaceuticals plc has disclosed that the High Court of Ireland has scheduled a hearing for February 10, 2026, to consider the company’s application regarding the proposed acquisition by Alkermes plc. The court will review the plan under which Alkermes would acquire all outstanding shares of Avadel. The transaction is expected to close shortly after the court issues its decision.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avadel Pharmaceuticals plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 20, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260120:nNDL8ml2dQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALKS","AVDL","BK4139","BK4007"],"gpt_icon":0},{"id":"2603526374","title":"Avadel Shareholders Approve Acquisition by Alkermes","url":"https://stock-news.laohu8.com/highlight/detail?id=2603526374","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603526374?lang=en_us&edition=fundamental","pubTime":"2026-01-13 05:05","pubTimestamp":1768251949,"startTime":"0","endTime":"0","summary":"Avadel Pharmaceuticals shareholders have approved the proposed acquisition by Alkermes plc. At meetings held earlier today, Avadel shareholders voted in favor of Alkermes acquiring the entire issued and to be issued ordinary share capital of the company. The resolutions related to the transaction received strong support, with 97.41% of votes cast in favor at the scheme meeting. Additionally, Avadel shareholders approved, on a non-binding, advisory basis, the specified compensatory arrangements for the company’s named executive officers in connection with the transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avadel Pharmaceuticals plc published the original content used to generate this news brief via GlobeNewswire  on January","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDLbHztPK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","LU2095319765.USD","SG9999014021.USD","IE00B3QW5Z07.USD","NDAQ","BK4585","IE00BGHQF748.EUR","LU2210150020.SGD","SG9999014005.SGD","SG9999014013.SGD","BK4112","AVDL","BK4007","BK4139","IE00B64PRP62.GBP","LU0314104364.USD","IE00BKPKM429.USD","BK4588","LU2210149790.SGD","ALKS"],"gpt_icon":0},{"id":"2603397526","title":"Avadel Pharmaceuticals Announces That Avadel Shareholders Approve the Proposed Acquisition by Alkermes","url":"https://stock-news.laohu8.com/highlight/detail?id=2603397526","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603397526?lang=en_us&edition=fundamental","pubTime":"2026-01-13 05:05","pubTimestamp":1768251901,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nTUA8HWCST:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AVDL","BK4007"],"gpt_icon":0},{"id":"2592179153","title":"Assessing Avadel Pharmaceuticals (AVDL) Valuation After a Strong 1-Year Share Price Rally","url":"https://stock-news.laohu8.com/highlight/detail?id=2592179153","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592179153?lang=en_us&edition=fundamental","pubTime":"2025-12-19 13:19","pubTimestamp":1766121546,"startTime":"0","endTime":"0","summary":"Avadel Pharmaceuticals (AVDL) has quietly turned into one of those under the radar movers, with the stock nearly doubling this year even after a recent pullback over the past month.\nSee our latest analysis for Avadel Pharmaceuticals.\nWith the share price now at $21.42, Avadel’s roughly 32% 3 month share price return and 107.76% 1 year total shareholder return suggest momentum is still building as investors reassess its growth runway and risk profile.\nIf Avadel’s run has you rethinking your...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-avdl/avadel-pharmaceuticals/news/assessing-avadel-pharmaceuticals-avdl-valuation-after-a-stro","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-avdl/avadel-pharmaceuticals/news/assessing-avadel-pharmaceuticals-avdl-valuation-after-a-stro","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["AVDL","BK4007","DCF"],"gpt_icon":0},{"id":"2592908419","title":"Avadel Pharmaceuticals Completes Enrollment in Phase 3 Trial of LUMRYZ for Idiopathic Hypersomnia","url":"https://stock-news.laohu8.com/highlight/detail?id=2592908419","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592908419?lang=en_us&edition=fundamental","pubTime":"2025-12-18 20:01","pubTimestamp":1766059292,"startTime":"0","endTime":"0","summary":"Avadel Pharmaceuticals plc announced the completion of patient enrollment in the Phase 3 REVITALYZ trial, which is evaluating LUMRYZ  extended-release oral suspension as a potential treatment for idiopathic hypersomnia. The study is a double-blind, placebo-controlled, randomized withdrawal, multicenter trial assessing both patients switching from immediate-release oxybates and those not currently taking oxybates. The primary endpoint is the change in total score on the Epworth Sleepiness Scale at Week 14, with secondary endpoints evaluating additional efficacy measures. Data from the trial are expected in the second quarter of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avadel Pharmaceuticals plc published the original content","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nNDL8XG4L1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014021.USD","IE00B64PRP62.GBP","BK4007","SG9999014005.SGD","LU2210149790.SGD","BK4585","LU2095319765.USD","NDAQ","LU2210150020.SGD","SG9999014039.USD","AVDL","SG9999014013.SGD","IE00BKPKM429.USD","IE00BGHQF748.EUR","BK4112","BK4588","LU0314104364.USD","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2592908618","title":"Avadel Pharmaceuticals Announces Completion of Enrollment in Phase 3 Revitalyz™ Trial in Idiopathic Hypersomnia","url":"https://stock-news.laohu8.com/highlight/detail?id=2592908618","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592908618?lang=en_us&edition=fundamental","pubTime":"2025-12-18 20:00","pubTimestamp":1766059200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nTUA8KD58W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AVDL","BK4007"],"gpt_icon":0},{"id":"2592908112","title":"Avadel Pharmaceuticals Plc - Data Expected in Q2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2592908112","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592908112?lang=en_us&edition=fundamental","pubTime":"2025-12-18 20:00","pubTimestamp":1766059200,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nTUA8KD58W:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AVDL","BK4007"],"gpt_icon":0},{"id":"2590248523","title":"HSR Waiting Period Expires for Avadel Pharmaceuticals Acquisition by Alkermes","url":"https://stock-news.laohu8.com/highlight/detail?id=2590248523","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590248523?lang=en_us&edition=fundamental","pubTime":"2025-12-10 05:16","pubTimestamp":1765315000,"startTime":"0","endTime":"0","summary":"Avadel Pharmaceuticals plc disclosed that the waiting period for regulatory review has expired regarding the planned acquisition of Avadel by Alkermes plc. This development marks the satisfaction of a key condition for the closing of the transaction. Completion of the acquisition remains subject to additional customary conditions, including approval by Avadel shareholders and final approval by the Irish High Court.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avadel Pharmaceuticals plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 09, 2025, and is solely responsible for the i","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nNDL3mMz2p:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVDL","BK4139","BK4007","ALKS"],"gpt_icon":0},{"id":"2588228210","title":"Press Release: Announcement relating to despatch of Definitive Proxy Statement and details of Scheme Meeting and Extraordinary General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2588228210","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588228210?lang=en_us&edition=fundamental","pubTime":"2025-12-04 05:47","pubTimestamp":1764798420,"startTime":"0","endTime":"0","summary":"DUBLIN, Dec. 03, 2025  -- As previously announced, the board of directors of Avadel Pharmaceuticals plc , a public limited company incorporated in Ireland  and the board of directors of Alkermes plc, a public limited company incorporated in Ireland , reached agreement on the terms of an offer for the Company by Alkermes, pursuant to which Alkermes will acquire the entire issued and to be issued ordinary share capital of the Company . As outlined in both the announcement made by the Company and Alkermes under Rule 2.7 of the Irish Takeover Rules on October 22, 2025, and in the revised offer announcement made by the Company and Alkermes on November 19, 2025, the Proposed Transaction is to be implemented by way of a scheme of arrangement under Chapter 1 of Part 9 of the Irish Companies Act 2014 .Avadel Pharmaceuticals plc  is a biopharmaceutical company focused on transforming medicines to transform lives. Avadel's approach includes applying innovative solutions to the development of medi","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TM","BK4017","LU0724618789.USD","BK4161","AVDL","LU0330918003.SGD","BK4099","LU0055631609.USD","LU0788108826.HKD","03160","BK4588","LU0300736492.USD","B","LU0345780521.USD","LU0498741890.SGD","BK4604","LU0345780281.USD","BK4585","BK4007","LU0075056555.USD","BK4555","LU0496367417.USD","LU0368265764.SGD","LU0498741114.HKD","LU0300736062.USD","LU0788109121.HKD","LU1023059493.AUD"],"gpt_icon":0},{"id":"2588708036","title":"Avadel Pharmaceuticals Plc - Scheme Meeting and Egm Scheduled for January 12, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2588708036","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588708036?lang=en_us&edition=fundamental","pubTime":"2025-12-02 05:06","pubTimestamp":1764623185,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nFWN3X70R7:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BK4139","ALKS","AVDL"],"gpt_icon":0},{"id":"2586370248","title":"BUZZ-H Lundbeck steps down from takeover for Avadel, shares rise 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2586370248","media":"Reuters","labels":["shareholding","corporation","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586370248?lang=en_us&edition=fundamental","pubTime":"2025-11-27 16:29","pubTimestamp":1764232155,"startTime":"0","endTime":"0","summary":"BUZZ-H Lundbeck steps down from takeover for Avadel, shares rise 3%** Shares in H Lundbeck HLUNa.CO rise 3.3% after the Danish pharmaceutical company said it would not increase a purchase price in a takeover offer for Avadel Pharmaceuticals AVDL.O ** Lundbeck added that its strategic rationale for engaging in the sleep disorders space stays \"fully intact\"** The Danish company made an unsolicited bid for Avadel on November 14, offering up to $23 per share** Drugmaker Alkermes ALKS.O, who also made a bid for Avadel, sweetened its offer to $2.37 billion, which Avadel's board recommended to its shareholders on November 19** H Lundbeck shares were up 1.3% at 08:27 GMT  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251127:nL8N3X30AF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,corporation,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","ALKS","AVDL"],"gpt_icon":0},{"id":"2586260700","title":"Jefferies expects Avadel-Alkermes deal to close","url":"https://stock-news.laohu8.com/highlight/detail?id=2586260700","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586260700?lang=en_us&edition=fundamental","pubTime":"2025-11-27 05:05","pubTimestamp":1764191147,"startTime":"0","endTime":"0","summary":"Jefferies lowered the firm’s price target on Avadel Pharmaceuticals (AVDL) to $22.50 from $23 and keeps a Hold rating on the shares as the firm exp...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/jefferies-expects-avadel-alkermes-deal-to-close-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/jefferies-expects-avadel-alkermes-deal-to-close-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AVDL","BK4007"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.avadel.com","stockEarnings":[{"period":"1week","weight":-0.0023},{"period":"1month","weight":0.0065},{"period":"3month","weight":-0.0815},{"period":"6month","weight":0.5807},{"period":"1year","weight":1.4071},{"period":"ytd","weight":0.0042}],"compareEarnings":[{"period":"1week","weight":-0.0128},{"period":"1month","weight":-0.0125},{"period":"3month","weight":0.0146},{"period":"6month","weight":0.0595},{"period":"1year","weight":0.1181},{"period":"ytd","weight":-0.0002}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.","yearOnYearQuotes":[{"month":1,"riseRate":0.566667,"avgChangeRate":0.047861},{"month":2,"riseRate":0.5,"avgChangeRate":0.09577},{"month":3,"riseRate":0.448276,"avgChangeRate":-0.017439},{"month":4,"riseRate":0.482759,"avgChangeRate":0.020678},{"month":5,"riseRate":0.517241,"avgChangeRate":-0.004725},{"month":6,"riseRate":0.448276,"avgChangeRate":0.040203},{"month":7,"riseRate":0.4,"avgChangeRate":0.022136},{"month":8,"riseRate":0.433333,"avgChangeRate":0.041512},{"month":9,"riseRate":0.366667,"avgChangeRate":-0.024246},{"month":10,"riseRate":0.4,"avgChangeRate":0.008337},{"month":11,"riseRate":0.533333,"avgChangeRate":0.055436},{"month":12,"riseRate":0.482759,"avgChangeRate":0.035745}],"exchange":"NASDAQ","name":"Avadel Pharmaceuticals plc","nameEN":"Avadel Pharmaceuticals plc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Avadel Pharmaceuticals plc(AVDL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Avadel Pharmaceuticals plc(AVDL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Avadel Pharmaceuticals plc,AVDL,Avadel Pharmaceuticals plc股票,Avadel Pharmaceuticals plc股票老虎,Avadel Pharmaceuticals plc股票老虎国际,Avadel Pharmaceuticals plc行情,Avadel Pharmaceuticals plc股票行情,Avadel Pharmaceuticals plc股价,Avadel Pharmaceuticals plc股市,Avadel Pharmaceuticals plc股票价格,Avadel Pharmaceuticals plc股票交易,Avadel Pharmaceuticals plc股票购买,Avadel Pharmaceuticals plc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Avadel Pharmaceuticals plc(AVDL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Avadel Pharmaceuticals plc(AVDL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction